Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance

Calvo, T. ; Reina-Ortiz, C. ; Giraldos, D. ; Gascón, M. (Universidad de Zaragoza) ; Woods, D. ; Asenjo, J. ; Marco-Brualla, J. ; Azaceta, G. (Universidad de Zaragoza) ; Izquierdo, I. (Universidad de Zaragoza) ; Palomera, L. (Universidad de Zaragoza) ; Sánchez-Martínez, D. ; Marzo, I. (Universidad de Zaragoza) ; Naval, J. (Universidad de Zaragoza) ; Vilches, C. ; Villalba, M. ; Anel, A. (Universidad de Zaragoza)
Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance
Resumen: Adoptive transfer of allogeneic natural killer (NK) cells is becoming a credible immunotherapy for hematological malignancies. In the present work, using an optimized expansion/activation protocol of human NK cells, we generate expanded NK cells (eNK) with increased expression of CD56 and NKp44, while maintaining that of CD16. These eNK cells exerted significant cytotoxicity against cells from 34 B-CLL patients, with only 1 sample exhibiting resistance. This sporadic resistance did not correlate with match between KIR ligands expressed by the eNK cells and the leukemic cells, while cells with match resulted sensitive to eNK cells. This suggests that KIR mismatch is not relevant when expanded NK cells are used as effectors. In addition, we found two examples of de novo resistance to eNK cell cytotoxicity during the clinical course of the disease. Resistance correlated with KIR-ligand match in one of the patients, but not in the other, and was associated with a significant increase in PD-L1 expression in the cells from both patients. Treatment of one of these patients with idelalisib correlated with the loss of PD-L1 expression and with re-sensitization to eNK cytotoxicity. We confirmed the idelalisib-induced decrease in PD-L1 expression in the B-CLL cell line Mec1 and in cultured cells from B-CLL patients. As a main conclusion, our results reinforce the feasibility of using expanded and activated allogeneic NK cells in the treatment of B-CLL.
Idioma: Inglés
DOI: 10.1038/s41598-020-76051-z
Año: 2020
Publicado en: Scientific Reports 10, 1 (2020), 19398 [14 pp]
ISSN: 2045-2322

Factor impacto JCR: 4.379 (2020)
Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 17 / 73 = 0.233 (2020) - Q1 - T1
Factor impacto SCIMAGO: 1.24 - Multidisciplinary (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B31-17R
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2016-76338-R
Tipo y forma: Article (Published version)
Área (Departamento): Area Anatom.Embriol.Humana (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Exportado de SIDERAL (2021-09-02-10:38:25)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2020-12-16, last modified 2021-09-02

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)